Purpose of Review. The adaptive immune response orchestrated by type 2 T helper (Th2) lymphocytes, strictly cooperates with the innate response of group 2 innate lymphoid cells (ILC2), in the protection from helminths infection, as well as in the pathogenesis of allergic disease. The aim of this review is to explore the pathogenic role of ILC2 in different type 2-mediated disorders. Recent Findings. Recent studies have shown that epithelial cell-derived cytokines and their responding cells, ILC2, play a pathogenic role in bronchial asthma, chronic rhinosinusitis, and atopic dermatitis. Summary. The growing evidences of the contribution of ILC2 in the induction and maintenance of allergic inflammation in such disease suggest the possibility to target them in therapy. Biological therapies blocking ILC2 activation or neutralizing their effector cytokines are currently under evaluation to be used in patients with type 2-dominated diseases.

Role of Type 2 Innate Lymphoid Cells in Allergic Diseases / Cosmi, Lorenzo; Liotta, Francesco; Maggi, Laura; Annunziato, Francesco. - In: CURRENT ALLERGY AND ASTHMA REPORTS. - ISSN 1529-7322. - STAMPA. - 17:(2017), pp. 1-7. [10.1007/s11882-017-0735-9]

Role of Type 2 Innate Lymphoid Cells in Allergic Diseases

COSMI, LORENZO;LIOTTA, FRANCESCO;MAGGI, LAURA;ANNUNZIATO, FRANCESCO
2017

Abstract

Purpose of Review. The adaptive immune response orchestrated by type 2 T helper (Th2) lymphocytes, strictly cooperates with the innate response of group 2 innate lymphoid cells (ILC2), in the protection from helminths infection, as well as in the pathogenesis of allergic disease. The aim of this review is to explore the pathogenic role of ILC2 in different type 2-mediated disorders. Recent Findings. Recent studies have shown that epithelial cell-derived cytokines and their responding cells, ILC2, play a pathogenic role in bronchial asthma, chronic rhinosinusitis, and atopic dermatitis. Summary. The growing evidences of the contribution of ILC2 in the induction and maintenance of allergic inflammation in such disease suggest the possibility to target them in therapy. Biological therapies blocking ILC2 activation or neutralizing their effector cytokines are currently under evaluation to be used in patients with type 2-dominated diseases.
2017
17
1
7
Goal 3: Good health and well-being for people
Cosmi, Lorenzo; Liotta, Francesco; Maggi, Laura; Annunziato, Francesco
File in questo prodotto:
File Dimensione Formato  
CosmiL 2017.pdf

Accesso chiuso

Tipologia: Pdf editoriale (Version of record)
Licenza: Tutti i diritti riservati
Dimensione 1.48 MB
Formato Adobe PDF
1.48 MB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1101801
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 46
  • ???jsp.display-item.citation.isi??? 43
social impact